CTSO Cytosorbents Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1175151 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.1%
TTM net income YoY-84.6%
TTM EPS YoY-61.1%
Revenue 3-yr CAGR0.8%
Net income 3-yr CAGR—
Margins
Gross margin71.6%
Operating margin-34.7%
Net margin-48.9%
FCF margin-25.0%
EBITDA margin-32.1%
Returns
ROE-336.2%
ROA-42.4%
ROIC (approx.)-73.4%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets102.0%
Debt / equity—
Current ratio0.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $37.06M | $35.59M |
| Cost of revenue | $10.57M | $10.71M |
| Gross profit | $26.49M | $24.89M |
| SG&A expense | $35.65M | $33.73M |
| Operating income | -$14.75M | -$16.45M |
| Pretax income | -$8.60M | -$22.41M |
| Income tax | -$401,000 | -$1.69M |
| Net income | -$8.20M | -$20.72M |
| EBITDA | -$13.52M | -$15.12M |
| EPS (basic) | -0.13 | -0.38 |
| EPS (diluted) | -0.13 | -0.38 |
| Weighted avg. shares (diluted) | 62.23M | 54.43M |
| Balance sheet | ||
| Cash & equivalents | $6.25M | $9.76M |
| Receivables | $7.55M | $7.32M |
| Inventory | $5.28M | $2.73M |
| Current assets | $20.63M | $21.60M |
| PP&E, net | $7.82M | $9.00M |
| Intangibles | $3.23M | $3.72M |
| Total assets | $44.18M | $47.37M |
| Current liabilities | $9.71M | $9.82M |
| Long-term debt | $16.67M | $14.00M |
| Total debt | $16.67M | $14.00M |
| Total liabilities | $38.28M | $36.27M |
| Shareholders' equity | $5.90M | $11.11M |
| Net debt | $10.42M | $4.23M |
| Shares outstanding | 62.80M | 54.83M |
| Cash flow statement | ||
| Operating cash flow | -$12.38M | -$14.43M |
| Capital expenditure | $164,000 | $284,000 |
| Free cash flow | -$12.54M | -$14.71M |
| Investing cash flow | -$415,000 | -$669,000 |
| Financing cash flow | $9.31M | $9.33M |
| Depreciation & amortization | $1.23M | $1.33M |
| Stock-based compensation | $2.77M | $3.76M |
Free plan shows the latest 2 periods; Pro shows all 29 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.